Lumexa Imaging Holdings/$LMRI
1D1W1MYTD1Y5YMAX
Capital at risk
About Lumexa Imaging Holdings
Lumexa Imaging Holdings Inc is a provider of diagnostic imaging services. The company offers a broad range of imaging modalities, including MRI, CT, PET, X-ray, ultrasound, and mammography. Its products and operations are managed and reported in two operating segments: Outpatient Imaging Centers (Outpatient) and Professional Services (Professional). The professional services segment generates revenue from interpreting imaging studies conducted by other parties, mainly hospital imaging departments. The majority of revenue is generated by the Outpatient segment, which performs imaging studies and provides radiologists' interpretations of those studies.
- Ticker
- $LMRI
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 4,200
- Headquarters
- Raleigh, United States
- Website
- www.lumexaimaging.com
LMRI Metrics
BasicAdvanced
$1.1B
-
-$0.33
-
-
Price and volume
Market cap
$1.1B
52-week high
$19.45
52-week low
$6.45
Average daily volume
430K
Financial strength
Current ratio
1.438
Quick ratio
1.356
Long term debt to equity
1.517
Total debt to equity
1.586
Interest coverage (TTM)
0.43%
Profitability
EBITDA (TTM)
78.174
Gross margin (TTM)
14.90%
Net profit margin (TTM)
-2.66%
Operating margin (TTM)
3.46%
Effective tax rate (TTM)
-66.56%
Revenue per employee (TTM)
$250,000
Management effectiveness
Valuation
Price to revenue (TTM)
0.93
Price to book
1.8
Price to tangible book (TTM)
-4.77
Price to free cash flow (TTM)
31.056
Free cash flow yield (TTM)
3.22%
Free cash flow per share (TTM)
0.371
Growth
Bulls say / Bears say
Consolidated same-center advanced outpatient volume growth of 5.2% and system-wide growth of 4.9% in Q2 2026 underscores robust demand for higher-margin imaging services. (Nasdaq)
Balance sheet strengthened with leverage reduced by two turns following IPO-driven debt repayment, enhancing financial flexibility and reducing interest expense. (SEC)
Launched its first de novo outpatient imaging center in February 2026 as part of a strategy to open eight–ten new centers annually, expanding its growth pipeline. (Lumexa)
System-wide same-center revenue growth of just 4.4% in Q2 2026 and 3.6% for the first half highlights limited organic expansion and mounting competitive pressures. (SEC)
Long-term debt remained at $835.4 million (net of issuance costs) with $32.6 million of interest expense in H1 2026, underscoring ongoing high leverage and interest charges. (StockTitan)
Quarterly results are subject to seasonality from annual deductible resets and weather events, indicating potential volatility in outpatient volumes and revenue. (Lumexa)
Data summarised monthly by Lightyear AI. Last updated on 24 Aug 2026.
Upcoming events
No upcoming events
LMRI News
AllArticlesVideos
Funds containing LMRI
Fund name | Fund size | $LMRI weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.